GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd (SHSE:600329) » Definitions » Beneish M-Score

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Beneish M-Score : -2.65 (As of Dec. 12, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Tianjin Pharmaceutical Da Ren Tang Group Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.65 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Tianjin Pharmaceutical Da Ren Tang Group's Beneish M-Score or its related term are showing as below:

SHSE:600329' s Beneish M-Score Range Over the Past 10 Years
Min: -2.66   Med: -2.34   Max: -1.87
Current: -2.65

During the past 13 years, the highest Beneish M-Score of Tianjin Pharmaceutical Da Ren Tang Group was -1.87. The lowest was -2.66. And the median was -2.34.


Tianjin Pharmaceutical Da Ren Tang Group Beneish M-Score Historical Data

The historical data trend for Tianjin Pharmaceutical Da Ren Tang Group's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianjin Pharmaceutical Da Ren Tang Group Beneish M-Score Chart

Tianjin Pharmaceutical Da Ren Tang Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.39 -2.34 -2.64 -2.13 -2.22

Tianjin Pharmaceutical Da Ren Tang Group Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.32 -2.22 -1.94 -2.66 -2.65

Competitive Comparison of Tianjin Pharmaceutical Da Ren Tang Group's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Tianjin Pharmaceutical Da Ren Tang Group's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tianjin Pharmaceutical Da Ren Tang Group's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tianjin Pharmaceutical Da Ren Tang Group's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Tianjin Pharmaceutical Da Ren Tang Group's Beneish M-Score falls into.



Tianjin Pharmaceutical Da Ren Tang Group Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Tianjin Pharmaceutical Da Ren Tang Group for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0735+0.528 * 0.9091+0.404 * 1.0433+0.892 * 0.9482+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0737+4.679 * -0.02211-0.327 * 1.1336
=-2.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Total Receivables was ¥2,910 Mil.
Revenue was 1646.192 + 1879.152 + 2085.588 + 2429.272 = ¥8,040 Mil.
Gross Profit was 767.916 + 904.619 + 1074.972 + 1019.373 = ¥3,767 Mil.
Total Current Assets was ¥7,122 Mil.
Total Assets was ¥10,970 Mil.
Property, Plant and Equipment(Net PPE) was ¥1,454 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥1,896 Mil.
Total Current Liabilities was ¥4,192 Mil.
Long-Term Debt & Capital Lease Obligation was ¥217 Mil.
Net Income was 146.137 + 270.393 + 387.326 + 128.515 = ¥932 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was 12.394 + 644.514 + -89.299 + 607.303 = ¥1,175 Mil.
Total Receivables was ¥2,858 Mil.
Revenue was 1704.731 + 1933.903 + 2154.406 + 2686.238 = ¥8,479 Mil.
Gross Profit was 683.011 + 864.931 + 1050.913 + 1012.746 = ¥3,612 Mil.
Total Current Assets was ¥6,708 Mil.
Total Assets was ¥10,282 Mil.
Property, Plant and Equipment(Net PPE) was ¥1,423 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥1,862 Mil.
Total Current Liabilities was ¥3,404 Mil.
Long-Term Debt & Capital Lease Obligation was ¥242 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(2909.517 / 8040.204) / (2858.366 / 8479.278)
=0.361871 / 0.3371
=1.0735

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(3611.601 / 8479.278) / (3766.88 / 8040.204)
=0.425933 / 0.468506
=0.9091

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (7122.031 + 1453.513) / 10969.53) / (1 - (6707.646 + 1423.33) / 10281.701)
=0.21824 / 0.20918
=1.0433

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=8040.204 / 8479.278
=0.9482

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 1423.33)) / (0 / (0 + 1453.513))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1895.72 / 8040.204) / (1862.028 / 8479.278)
=0.23578 / 0.219597
=1.0737

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((217.293 + 4191.931) / 10969.53) / ((242.04 + 3403.691) / 10281.701)
=0.401952 / 0.354584
=1.1336

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(932.371 - 0 - 1174.912) / 10969.53
=-0.02211

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Tianjin Pharmaceutical Da Ren Tang Group has a M-score of -2.65 suggests that the company is unlikely to be a manipulator.


Tianjin Pharmaceutical Da Ren Tang Group Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Tianjin Pharmaceutical Da Ren Tang Group's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Tianjin Pharmaceutical Da Ren Tang Group Business Description

Traded in Other Exchanges
Address
No. 17 Baidi Road, Zhong Xin Mansion, Nankai District, Tianjin, CHN, 300193
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company manufactures and sells traditional Chinese medicine, western medicine, and healthcare products in the People's Republic of China. It operates in two segments namely The Chinese Medicine segment and The Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese pharmaceutical products.
Executives
Li Li Qun Director
Ni Zhen Guo senior management
Yu Hong Directors, senior managers
Zhou Hong Directors, senior managers
Zhang Jian senior management
Niu Sheng Fang senior management
Wang Xin senior management
Wang Mai Director
Jiao Yan senior management
Hao Fei Fei Director
Zhang Bao Tong senior management
Wang Zhi Qiang senior management
Liang Xiu Qin senior management
Li Jia Sheng Supervisors
Zhang Hong Kui Director

Tianjin Pharmaceutical Da Ren Tang Group Headlines

No Headlines